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Abstract
Purpose of Review Multiple myeloma is the second most common hematologic malignancy in the USA, with over 32,000 new
cases and nearly 13,000 deaths expected in 2019. The past few decades in myeloma research have yielded significant advances,
leading to the expansion of novel anti-myeloma agents. This review describes the incidence and mechanisms of cardiotoxicity for
the FDA-approved proteasome inhibitors in myeloma and proposes strategies to assess and manage resultant cardiovascular
adverse events.
Recent Findings Proteasome inhibition precipitates protein aggregation and alters transcriptional activation of NF-κB targets
which contributes to a pro-apoptotic signaling cascade in myeloma cells. Similar effects in cardiomyocytes and vascular smooth
muscle endothelium, along with off-target downregulation of autophagy and signaling alterations of nitric oxide homeostasis,
may be linked to observed cardiotoxic effects. There is preliminary evidence for cardioprotective potential for rutin, dexrazoxane,
and apremilast that could have clinical applicability in the future.
Summary Of the proteasome inhibitors used in clinical practice, carfilzomib is the most strongly associated with cardiotoxicity.
Patients with anticipated carfilzomib treatment should undergo assessment and optimization of baseline cardiovascular risk, with
close monitoring during treatment. Previous clinical trials were not specifically designed to assess proteasome inhibitor-related
cardiotoxicity, creating a need for future studies to identify and risk stratify vulnerable individuals and to develop potential
cardioprotective strategies in attenuating cardiac injury.
Keywords Carfilzomib . Bortezomib . Chemotherapy-induced cardiomyopathy
Introduction
Multiple myeloma (MM) is the second most common hema-
tologic malignancy in the USA, with over 32,000 new cases
and nearly 13,000 deaths expected in 2019 [1]. The past few
decades in myeloma research have yielded significant
advances in the understanding and treatment of the disease,
leading to the expansion of novel anti-myeloma agents to
include immunomodulatory drugs (IMiDs) and proteasome
inhibitors (PIs) as well as advanced targeted therapies such
as epigenetic modulators and humanized monoclonal antibod-
ies. These developments have translated into improved long-
term clinical response and survival, with 5-year relative sur-
vival rates increased from the 1975–1977 rate of 25% to the
2008–2014 rate of 52% [1]. Moreover, the improved efficacy
and safety profile of these novel agents and the identification
of high-risk patients with smoldering multiple myeloma
(SMM) have influenced current trends of myeloma manage-
ment to favor treatment at an earlier point in the natural history
of the paraproteinemia using biochemical and radiographic
biomarkers [2]. Consequently, the management of chronic
treatment-related adverse effects has become a more pertinent
issue as the prognostic outlook of patients with various stages
of the plasma cell dyscrasia treated with advanced therapies
continues to improve.
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While the use of anti-myeloma therapies has allowed for
improvements in overall survival (OS), the post-treatment
course of the disease is frequently complicated by cardiovas-
cular adverse events (CVAEs) which in turn contribute to
treatment-associated morbidity and mortality [3]. The concept
of cardiotoxicity refers to the effect of antineoplastic interven-
tion on accelerating the onset of cardiovascular (CV) disease.
It also relates to its direct effect on the structure or function of
the heart and vasculature, including systemic hypertension,
myocardial dysfunction and congestive heart failure (CHF),
coronary heart disease, arrhythmias, thromboembolic disease,
pulmonary hypertension, valvular disease, pericardial compli-
cations, or other vascular diseases including stroke and pe-
ripheral vascular disease [4]. The exact risk conferred by
anti-myeloma agents, as shown in clinical trials, may vary
depending on which endpoints were used to define
cardiotoxicity. For example, the imaging modality used for
detection of left ventricular ejection fraction (LVEF), the de-
gree of drop in LVEF, as well as the clinical assessment of
CHF vary between studies. In addition, current data about
cardiotoxicity were generated in clinical trials from which
patients with severe pre-existing CV comorbidities were often
excluded. Despite these uncertainties, there is mounting evi-
dence and concern in clinical practice for cardiotoxicity me-
diated by newer antineoplastic agents in MM, especially with
PIs, a medication class that has emerged as the backbone of
combined therapy for relapsed or refractory MM (RRMM) as
well as newly-diagnosed multiple myeloma (NDMM).
Currently, there are no validated protocols or established
guidelines to help identify patients at high risk of CV toxicity
during PI therapy or to manage associated cardiotoxicity. This
review provides an overview of the clinical data leading to
FDA approval of the presently available PIs along with known
associated CVAEs. We present mechanistic insights into pro-
teasome inhibition and its effects on malignant plasma cells as
well as the unintended consequences of cardiomyocyte and
endothelial cell impairment. We conclude by outlining current
and anticipated methods of diagnosis and management of pro-
teasome inhibitor-related cardiotoxicity.
Baseline Cardiovascular Adverse Events (CVAEs)
in Multiple Myeloma
Themedian age of diagnosis ofMM is approximately 70 years
[5]. Since the disease predominantly affects the elderly, a sig-
nificant proportion of patients with MM have cardiovascular
risk factors or comorbidities at the time of diagnosis. A retro-
spective cohort study of 32,193 patients with NDMM or
RRMM in the USA demonstrated the presence of cardiac
comorbidities in nearly 2/3 of patients at baseline, with most
frequently observed conditions including ischemic heart dis-
ease (IHD), arrhythmia, and CHF [6]. Aspects related to the
features of MM itself also serve as risk factors that can
contribute to cardiovascular complications. The CRAB fea-
tures of MM (elevated calcium, renal insufficiency, anemia,
and bone lesions) [7] all have potential to lead to cardiovas-
cular manifestations: severe hypercalcemia can cause life-
threatening arrhythmias, renal insufficiency increases the risk
of CV disease 2–4 fold [8], anemia is independently associat-
ed with increased CVD risk [9] and can lead to arrhythmias
and hypertension [10], and AV shunts in the context of bone
lesions can lead to heart failure. Accumulation of amyloid
light-chain immunoglobulins can lead to overt clinical AL
amyloidosis in up to 15% of patients with MM as well as
clinically occult amyloid deposits in up to 38% of patients
during the course of their disease, and may present as heart
failure when there is cardiac involvement [11]. Similar to
cases of senile amyloidosis in which wild type transthyretin
(ATTRwt) deposits in the heart, AL amyloidosis also impairs
diastolic function with heart failure with preserved ejection
fraction (HFpEF), a diagnosis which may be identified with
non-invasive lab (BNP, troponin) and imaging data (echocar-
diography or radionucleotide imaging) [12].
Given that patients with MM already have an elevated risk
of CV disease at the time of diagnosis, early identification of
patients at high risk for CVAEs becomes important as these
patients may require more extensive and careful monitoring
prior to the initiation of cardiotoxic therapies. Co-
management of the underlying hematologic disorder along-
side with a cardiology-based discussion is essential in individ-
uals who are deemed to have a higher likelihood of develop-
ing clinical cardiovascular impairment during or after treat-
ment. In the same vein, since PIs have become a centerpiece
of the treatment of MM, it is important to recognize the spe-
cific cardiotoxic risks associated with the FDA-approved
drugs bortezomib, carfilzomib, and ixazomib, as well as
newer agents undergoing investigation including marizomib
and oprozomib.
Pre-Clinical Data and Mechanistic Underpinnings
to Explain PI-Related Cardiotoxicity
Understanding the mechanisms of PI cardiotoxicity may help
facilitate the development of methods for prevention or treat-
ment of cardiotoxicity (Fig. 1). In pre-clinical studies with
rats, it was found that carfilzomib accumulated in the heart
and led to strong inhibition of the cardiac proteasome [14].
Cardiomyocytes are especially sensitive to proteasome inhibi-
tion, as they are non-proliferative and have elevated protea-
some activity compared with other tissues [15]. In myeloma
cells, proteasome inhibition results in rapid accumulation of
incompatible regulatory proteins within the endoplasmic re-
ticulum (ER). This ER stress culminates in unfolded protein
response (UPR) with induction of apoptotic cascade [16].
Likewise, in cardiomyocytes, the inhibition of proteasomal-
dependent protein turnover of sarcomeres can lead to
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imbalance of proteins, with abnormal accumulation of
ubiquitinated proteins that associate with one another to form
sequentially higher order protein aggregates toxic to cellular
function [17]. These may include soluble oligomers and
aggresomes that eventually create insoluble inclusion bodies,
resulting in cellular injury that can ultimately lead to caspase-
mediated apoptosis and cell death [18, 19]. Abnormal protein
aggregates have been found in human cardiomyopathies in-
cluding HCM,DCM, and desmin-related cardiomyopathies as
well as heart failure [19–22].
Signaling cascades leading to maladaptive hypertrophy in
cardiomyocytes may be activated with proteasome inhibitor
treatment. The prominent role of transcription factor nuclear
factor kappa B (NF-κB) in promoting myelomagenesis pro-
vided the initial basis for targeting the proteasome in multiple
myeloma [23, 24]. Bortezomib cytotoxicity in MM may be
explained by the blockade of proteasomal processing of p100
to p52, a mediator in the noncanonical NF-κB pathway [25].
However, in cell lines with primarily canonical NF-κB path-
way signaling, proteasome inhibition with both bortezomib
and boronic acid MLN-273 resulted in IKKβ-dependent in-
creased phosphorylation and downregulation of IκBα which
activated NF-κB via the canonical pathway [25]. This sug-
gests that PIs may exhibit unique patterns of NF-κB activity
in different cell lines. The transcriptional activation of NF-κB
plays a major role in the pathophysiology of many cardiovas-
cular diseases, in some cases leading to pathologic remodel-
ing. For example, in the ischemia/reperfusion model follow-
ing myocardial infarction, NF-κB is activated downstream of
mitogen-activated protein kinase (MAPK) signal transduction
cascades such as extracellular signal-regulated kinases
(ERKs), c-Jun NH2-terminal kinases (JNKs), and p38
Fig. 1 Proteasome inhibitor-related cardiotoxicity—mechanistic
underpinnings [33••, 13]. The ubiquitin-proteasome system (UPS) plays
a central role in non-lysosomal protein quality control, allowing
eukaryotic cells to maintain normal cellular homeostasis and adapt to
physiologic changes. Proteins that are destined for turnover are tagged
with polyubiquitin chains by ubiquitin conjugation system and are
recognized by the proteasome complex which participates in the vast
majority of regulated intracellular proteolysis including both short-lived
and long-lived proteins. Studies in animal models suggest that
proteasome inhibition with bortezomib and MLN-273 (shown in lilac)
may cause IKKβ-dependent increased phosphorylation and
downregulation of IκBα which activates NF-κB, with many
downstream effects. Inhibition of proteasomal-dependent protein
turnover of sarcomeres can lead to the abnormal accumulation of
ubiquitinated proteins that associate with one another to form
sequentially higher order protein aggregates toxic to cellular function,
contributing to increased mitochondrial dysfunction and sarcoplasmic/
endoplasmic reticulum stress. Recent data with carfilzomib (shown in
red) suggest that its cardiotoxicity may stem from off-target effects of
the drug, resulting in activation of PP2A and inactivation of
downstream autophagy signaling. Treatment with proteasome
inhibitors, including carfilzomib, may result in uncoupled eNOS
expression with increased production of reactive oxygen species which
further exacerbates cardiotoxicity. Key: AMPKα AMP-activated protein
kinase; CFZ carfilzomib; IKKβ inhibitor of nuclear factor kappa-B
kinase subunit beta; IκBα nuclear factor of kappa light polypeptide
gene enhancer in B cells inhibitor alpha; LC3BII light chain 3B II;
NFκB nuclear factor kappa-light-chain-enhancer of activated B cells; PI
proteasome inhibitor; PI3K phosphoinositide 3-kinase; PIP2
phosphatidylinositol 4,5-bisphosphate; PIP3 phosphatidylinositol
(3,4,5)-trisphosphate; PP2A protein phosphatase 2A; PTEN
phosphatase and tensin homolog; ROS reactive oxygen species; Raptor
regulatory-associated protein of mTOR; Ub ubiquitin; eNOS endothelial
nitric oxide synthase; iNOS inducible nitric oxide synthase; mTOR
mammalian target of rapamycin
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[26–28]. While this signaling may be cardioprotective in the
short term by preventing apoptosis, prolonged activation of
NF-κBmay be detrimental and promotes heart failure through
chronic inflammation leading to ER stress responses and
death with accumulation of damaged or dying cardiomyocytes
[29]. Other signaling cascades such as NFAT-calcineurin acti-
vation leading to congestive heart failure was seen in mouse
models of desmin-related cardiomyopathy treated with rela-
tively higher doses of bortezomib [30]. In animals, protea-
some inhibition with bortezomib and MLN-273 has been
shown to induce left ventricular dysfunction with enlarged
cardiomyocytes demonstrating vacuolization, mitochondrial
dysfunction, and fibrosis [30–32]. Finally, a recent finding
describes off-target effects of carfilzomib in mice related to
activation of PP2A and inactivation of downstream signaling,
implicating the disruption of autophagy as a major contributor
to cardiotoxicity from the drug [33••]. This finding was not
reproduced with bortezomib and was unexpected when com-
pared with previous studies with other proteasome inhibitors.
This suggests that unique classes of proteasome inhibitors
may have distinct mechanisms for cardiotoxicity, an issue fur-
ther confounded by the utilization of different animal models.
Endothelial dysfunction in the vasculature is linked to the
cardiovascular effects, particularly hypertension, which is of-
ten seen in these patients [34]. One supporting finding is that
the majority of CVAEs are transient, with levels of natriuretic
peptides returning back to near-baseline values [35••].
Episodes of thrombotic microangiopathy have also been re-
ported, providing additional evidence for systemic endothelial
involvement [36]. Proteasome inhibition alters signaling in
vascular smooth muscle endothelium, leading to increased
vasoconstriction, vascular tone, vasospasms, and decreased
response to vasodilators such as nitric oxide and acetylcholine
[37–39]. Nitric oxide is converted from L-arginine by iso-
forms of nitric oxide synthase (NOS). Since the UPS plays a
significant role in endothelial NOS (eNOS) regulation, it is not
surprising that inhibition of the complex would impact down-
stream effectors [40]. In pigs, treatment with MLN 273 result-
ed in uncoupled eNOS expression, which was ultimately as-
sociated with increased coronary artery oxidative stress and
functional and structural changes to the heart consistent with a
hypertrophic-restrictive cardiomyopathy phenotype [31, 41].
It is conceivable that other PIs may have similar effects
in vivo. In addition, eNOS uncoupling in the vasculature leads
to the reduction of molecular oxygen to generate reactive ox-
ygen species (ROS) [42, 43]. In situations like diabetic car-
diomyopathy, ROS-driven pathways lead to hypertrophy and
fibrosis of the myocardium via NF-κB activation, leading to
increased inflammation and remodeling [44]. In murine stud-
ies, the increased formation of ROS has been hypothesized to
be the reason behind compounded and synergistic
cardiotoxicity from anthracyclines when used with protea-
some inhibition [45]. Along this vein, NO releasing agents
like nitrates or phosphodiesterase inhibitors may be useful in
treating carfilzomib-related adverse events. Alternatively, ni-
troglycerine and nifedipine may be useful to reduce vaso-
spasms associated with endothelial dysfunction.
Mechanism of Anti-Myeloma Efficacy and Evidence
of Cardiotoxicity for Currently FDA-Approved PIs
The barrel-shaped 20S catalytic core particle of the protea-
some degradation complex comprised four heptameric rings,
with two internalβ rings containing protease active sites com-
prised proteolytic subunits [46]. Subunitsβ1,β2, andβ5 have
caspase-like activity, trypsin-like activity, and chymotrypsin-
like activity respectively and mediate proteolytic cleavage. Of
note, immunoproteasome versions of these β subunits can be
found in lymphocytes and monocytes from IFN-γ and TNF-α
stimulation and are referred to as β1i, β2i, and β5i subunits.
Both the 20S constitutive proteasome and the 20s
immunoproteasomes are targeted by the currently FDA-
approved PIs which consist of bortezomib, carfilzomib, and
ixazomib as well as newer drugs in development including
oprozomib and marizomib (Table 1).
Bortezomib (BTZ, Velcade, PS-341)
Bortezomib is a PI that binds reversibly to the β5
(chymotrypsin-like) as well as β5i subunits of the
immunoproteasome [47]. The efficacy of bortezomib in clin-
ical practice was based on two large phase 2 studies: the
SUMMITand the CREST trials [48, 49]. Bortezomib received
accelerated approval by the FDA in 2003 for patients with
RRMM who have progressed after 3 or more prior lines of
therapy. In 2005, the phase 3 APEX trial compared outcomes
for patients who received bortezomib to patients who were
treated with the standard of care at that time, high-dose dexa-
methasone [50]. The outcomes of this international trial dem-
onstrated superior response rates, time to progression (TTP),
and OS in the bortezomib group, even in the context of more
than 62% of patients in the dexamethasone arm crossing over
to receive bortezomib. With this new evidence, bortezomib
emerged as the treatment of choice for relapsed MM as it
was approved by the FDA in 2005 for RRMM after failure
of 1 or more prior lines. Soon after, the FDA approved
bortezomib as an upfront treatment of NDMM in 2008 with
supporting data from the VISTA trial [51]. This trial became
especially relevant because it brought bortezomib in VMP
(bortezomib, melphalan, prednisone) combination therapy to
the forefront as the standard of care for induction therapy in
patients ineligible for ASCT.
Although there have been occasional case reports and se-
ries of cardiotoxicity from bortezomib leading to heart failure
[52–56], ischemic heart disease [57], and complete heart block
[58], the onset of cardiac symptoms has typically been
   66 Page 4 of 14 Curr Oncol Rep           (2020) 22:66 
Ta
bl
e
1
C
ur
re
nt
an
ti-
m
ye
lo
m
a
pr
ot
ea
so
m
e
in
hi
bi
to
rs
,m
ec
ha
ni
sm
s,
an
d
kn
ow
n
as
so
ci
at
ed
ca
rd
io
to
xi
ci
ty
D
ru
g
na
m
e
FD
A
ap
pr
ov
al
ye
ar
M
ec
ha
ni
sm
K
no
w
n
ca
rd
io
to
xi
ci
ty
R
ef
er
en
ce
s
B
or
te
zo
m
ib
(B
T
Z
,V
el
ca
de
,
P
S-
34
1)
20
03
(R
R
M
M
af
te
r
≥
3
pr
io
r
lin
es
of
th
er
ap
y)
,2
00
5
(R
R
M
M
af
te
r
≥
1
pr
io
r
lin
es
of
th
er
ap
y)
,2
00
8
(N
D
M
M
),
20
12
(s
ub
cu
ta
ne
ou
s
ro
ut
e)
,2
01
4
(r
et
re
at
m
en
t
in
re
la
ps
e)
R
ev
er
si
bl
e
bi
nd
in
g
to
β
5
an
d
β
5i
su
bu
ni
ts
O
nl
y
in
ca
se
st
ud
ie
s:
he
ar
tf
ai
lu
re
,
is
ch
em
ic
he
ar
td
is
ea
se
,c
om
pl
et
e
he
ar
tb
lo
ck
B
oc
ko
rn
y
et
al
.[
52
],
G
up
ta
et
al
.
[5
3]
,H
on
to
n
et
al
.[
54
],
V
oo
rt
m
an
an
d
G
ia
cc
on
e
[5
5]
,E
nr
ic
o
et
al
.
[5
6]
,T
ak
am
at
su
et
al
.[
57
],
D
as
an
u
[5
8]
C
ar
fi
lz
om
ib
(C
FZ
,K
yp
ro
lis
,
PR
-1
71
)
20
12
(R
R
M
M
af
te
r
≥
2
pr
io
r
lin
es
of
th
er
ap
y
in
cl
ud
in
g
bo
rt
ez
om
ib
an
d
an
IM
iD
)
Ir
re
ve
rs
ib
le
bi
nd
in
g
to
β
5
an
d
β
5i
su
bu
ni
ts
A
rr
hy
th
m
ia
s
(1
3.
3%
),
he
ar
tf
ai
lu
re
(7
.2
%
),
is
ch
em
ic
he
ar
td
is
ea
se
(3
%
),
ca
rd
io
m
yo
pa
th
y
(2
%
),
pu
lm
on
ar
y
hy
pe
rt
en
si
on
(2
%
)
S
ie
ge
le
ta
l.
[6
9]
20
15
(i
n
K
R
d
re
gi
m
en
,R
R
M
M
af
te
r
≥
1
pr
io
r
lin
es
of
th
er
ap
y)
H
yp
er
te
ns
io
n
(4
.3
%
),
he
ar
tf
ai
lu
re
(3
.8
%
),
is
ch
em
ic
he
ar
td
is
ea
se
(3
.3
%
)
S
te
w
ar
te
ta
l.
[7
0]
,S
ie
ge
le
ta
l.
[7
1]
(A
S
P
IR
E
)
20
16
(i
n
K
d
re
gi
m
en
,R
R
M
M
af
te
r≥
1
pr
io
r
lin
es
of
th
er
ap
y)
H
yp
er
te
ns
io
n
(1
2.
2%
),
he
ar
tf
ai
lu
re
(4
.1
%
),
ar
rh
yt
hm
ia
s
(2
.4
%
),
is
ch
em
ic
he
ar
td
is
ea
se
(1
.8
%
)
W
ax
m
an
et
al
.[
75
••
]
N
/A
H
ea
rt
fa
ilu
re
(4
1%
),
hy
pe
rt
en
si
on
(2
3%
),
ar
rh
yt
hm
ia
(7
%
),
is
ch
em
ic
he
ar
td
is
ea
se
(6
%
),
pu
lm
on
ar
y
hy
pe
rt
en
si
on
(7
%
)
C
or
ne
ll
et
al
.[
35
••
]
(P
R
O
T
E
C
T,
C
F
Z
-b
as
ed
re
gi
m
en
m
os
t
co
m
m
on
ly
w
ith
po
m
al
id
om
id
e
an
d
de
xa
m
et
ha
so
ne
)
Ix
az
om
ib
(N
in
la
ro
,
M
L
N
97
08
)
20
15
(i
n
IL
d
re
gi
m
en
,R
R
M
M
af
te
r
≥
1
pr
io
r
lin
es
of
th
er
ap
y)
R
ev
er
si
bl
e
bi
nd
in
g
to
β
5
an
d
β
5i
su
bu
ni
ts
,i
nh
ib
iti
on
of
β
1
an
d
β
2
su
bu
ni
ts
at
hi
gh
co
nc
en
tr
at
io
ns
N
on
e
fo
un
d
in
T
O
U
R
M
A
L
IN
E
-M
M
1
tr
ia
l
M
or
ea
u
et
al
.[
79
•]
(T
O
U
R
M
A
L
IN
E
-M
M
1)
O
pr
oz
om
ib
(O
N
X
09
12
,
PR
-0
47
)
N
ot
ye
ta
pp
ro
ve
d
Ir
re
ve
rs
ib
le
bi
nd
in
g
to
β
5
an
d
β
5i
su
bu
ni
ts
U
nk
no
w
n
U
nk
no
w
n
M
ar
iz
om
ib
(N
PI
-0
05
2)
N
ot
ye
ta
pp
ro
ve
d
Ir
re
ve
rs
ib
le
bi
nd
in
g
to
β
5
an
d
β
2
su
bu
ni
ts
U
nk
no
w
n
U
nk
no
w
n
Curr Oncol Rep           (2020) 22:66 Page 5 of 14    66 
associated with a higher cumulative dose of the drug while
larger studies failed to demonstrate clinically significant
cardiotoxicity [59]. Of note, CVAEs were not closely moni-
tored or well reported in earlier trials, and the APEX trial was
the first to monitor cardiac events, with reports of similar
CVAEs in bortezomib and non-bortezomib groups (15% vs
13% of CVAEs). Both a 2014 meta-analysis of prospective
phase II and III trials evaluating bortezomib in cancer patients
(including MM, lymphoma, non-small-cell-lung cancer,
Waldenström’s macroglobulinemia, and ovarian cancer) with
cardiotoxicity data and a 2013 retrospective analysis of key
phase II and III trials with bortezomib in MM alone did not
show significant increased cardiotoxic effects from the drug
[60, 61]. Themain limitation of these large studies is that some
of the phase II and III trials did not adjudicate these endpoints
and thus may have generated incomplete data due to lack of
documentation regarding concomitant therapies or cardiovas-
cular comorbidities.
The mechanism for bortezomib chemoresistance has been
attributed to changes in expression of proteasome subunits
[62, 63]. While combination therapy may be effective in re-
sensitizing myeloma to PIs, there is both clinical and pre-
clinical data to suggest other proteasome inhibitors with irre-
versible binding to proteasome subunits, including
carfilzomib [64, 65], may subvert mechanisms of bortezomib
resistance.
Carfilzomib (CFZ, Kyprolis, PR-171)
Carfilzomib binds irreversibly to β5 (chymotryptic-like
activity) and β5i immunoproteasome, with equivalent poten-
cy against theβ5 and the LMP7 (β5i) subunits [66]. This drug
was found to have greater selectivity for β5 subunits, with
minimal affinity to β1 and β2 subunits when compared with
bortezomib [67]. Unlike boronates, carfilzomib has little af-
finity for off-target enzymes including serine proteases [14], a
mechanism for why carfilzomib is thought to be associated
with less treatment-induced peripheral neuropathy when com-
pared with bortezomib [68]. Carfilzomib was found to cause
proteasome inhibition in excess of 80% of patients [14], and
its efficacy in bortezomib-resistant lines may involve its abil-
ity to achieve prolonged and possibly more profound inhibi-
tion of the proteasome. However, although second-generation
PIs like carfilzomibmay exhibit favorable efficacy when com-
pared with bortezomib, they also present a unique toxicity
profile.
Carfilzomib received FDA approval in 2012 for use in
RRMM for patients who have received at least two prior ther-
apies including bortezomib and an IMiD, based on evidence
demonstrating improved overall response rates compared with
bortezomib in multiple multicenter phase II studies. However,
several early studies of carfilzomib noted an increased risk of
CVAEs. A pooled analysis of phase II studies with carfilzomib
(PX-171-003-A1, PX-171-003-A0, PX-171-004, and PX-
171-005) that included 526 patients showed 22% of patients
from these trials developed cardiac side effects: 13.3% expe-
rienced arrhythmias (mainly atrial fibrillation), 7.2% exhibited
heart failure, 2% developed treatment-associated cardiomyop-
athy, and 3% suffered from ischemic heart disease [69]. In
addition, 42% of these patients reported dyspnea.
In 2015, carfilzomib combination regimen with
lenalidomide and dexamethasone (KRd) was approved by
the FDA for RRMM with 1 or more prior lines based on
significantly improved PFS and improved quality of life with
KRd in the international, randomized, phase III ASPIRE trial
which compared KRd regimen with Rd. [70, 71••]. The
ASPIRE trial reported that the KRd group had increased cases
of CVAEwhen compared with Rd., with hypertension rates of
4.3% compared with 1.8%, heart failure rate of 3.8% com-
pared with 1.8%, and IHD rates of 3.3% compared with 2.1%.
Finally, in 2016, the FDA approved the use of carfilzomib
with low-dose dexamethasone (Kd) in patients with RRMM
for which 1 or more prior lines of therapy failed. This was
based on the results from phase III superiority trial,
ENDEAVOR, which compared Kd with bortezomib with
low-dose dexamethasone (Vd), which had been the standard
of care in RRMM [72, 73••]. Notably, the ENDEAVOR trial
excluded bortezomib-refractory patients as well as patients
with LVEF< 40% or clinical symptomsNYHA III/IVor recent
MI or symptoms of cardiac ischemia. In addition, rates of
grade 2 or higher peripheral neuropathy were seen in only
6% of the Kd group when compared with 32% of the Vd
group.
A pattern of increased cardiotoxicity has been demonstrat-
ed with carfilzomib. These toxicities include hypertension
(HTN), arrhythmia, heart failure (HF), ischemic heart disease
(IHD), cardiomyopathy, thromboembolic events, pulmonary
hypertension, and rarely sudden cardiac death [69, 74]. The
higher potency and irreversible inhibition by carfilzomib,
along with dose-limiting neuropathy associated with
bortezomib, may be the link between carfilzomib and higher
incidences of CVAEs. In the ENDEAVOR study, an expected
increased incidence of any-grade dyspnea, hypertension, and
heart failure were detected [73••]. However, the study only
reported clinically overt HF, biomarkers were not measured,
and LV function changes were only sequentiallymeasured in a
subpopulation analysis of 151 patients. For those patients,
serial echocardiography showed only two patients in each
group had reduced LVEF. In a systemic review and meta-
analysis of 24 prospective clinical trials that included 2594
patients found a large range of reported CVAEs, with all-
grade CVAE ranging from 0 to 52% and high-grade CVAE
ranging from 0 to 45% [75••]. Using a random effects model,
the study found an all-grade overall CVAE rate of 18.1% and
high-grade CVAE rate of 8.2%. The pronounced CV adverse
effects were heart failure (4.1%) and hypertension (12.2%),
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with lower risk of arrhythmias (2.4%) and ischemic events
(1.8%). All-grade dyspnea (23.9%) and edema (24.7%) were
common, although underlying causes were seldom document-
ed. CVAEs were especially significant with higher doses
(45 mg/m2 or higher). The study concluded that, based on
the 3 RCTs included in the study (ASPIRE, ENDEAVOR,
and FOCUS), the use of carfilzomib was associated with a
2-fold increased risk of high-grade CVAE. Another study an-
alyzing the safety profile across the RRMM clinical trials
demonstrated a risk profile that was transient and manageable
so that these risks were rarely associated with treatment dis-
continuation or dose reduction, while rates of fatal CVAEs
were not elevated.
In an effort to better define risk factors and outcomes in
patients who receive PI therapy, a prospective, observational
study, the PROTECT trial, was conducted [35••]. Of 95
RRMM patients enrolled, 65 were initiated on carfilzomib
therapy, and 30 treated on bortezomib. This was followed by
baseline assessments over 6 months with cardiac biomarkers
including troponin I or T, BNP, NT-proBNP, ECG, and echo-
cardiography, with monitoring over 18 months for the devel-
opment of CVAEs. The study found that a total of 64 CVAEs
occurred with 55% grade 3 or greater severity. Of these events,
51% were in patients treated with carfilzomib and 17% of
those were treated with bortezomib. The most common diag-
noses for carfilzomib-treated patients included 41% of cases
with all grades of heart failure and 21% of cases with grade 3
or 4 hypertension. Themedian time to first CVAEwas 31 days,
with 86% within the first 3 months. The study also demon-
strated an association between BNP and NT-proBNP rise and
increased CVAE risk, especially if natriuretic peptides were
elevated during the mid-first cycle of treatment. Levels of
troponin I or T, ECG, and echocardiographic parameters were
not predictive of CVAEs.
The PROTECT trial reported a much higher incidence of
CVAE than prior studies, possibly due to its prospective na-
ture as well as that CVAE were captured as a primary end-
point. However, it also points to the fact that patients in clin-
ical practice usually have higher incidence of cardiac comor-
bidities. The actual incidence and pathophysiology of CVAE
for carfilzomib-treated patients is unclear in the real world as
clinical trials often enroll healthy patients. A recently pub-
lished study that retrospectively assessed 635 patients treated
with carfilzomib in the general population using the
Surveillance, Epidemiology, and End Results (SEER)-
Medicare linked database from 2000 through 2013 for inci-
dence of cardiac adverse events, excluding pre-existing diag-
noses corresponding with these cardiac adverse events of in-
terest, found that 22% of patients developed hypertension and
14% developed heart failure [76••].
In many of the aforementioned trials, assessment for
CVAEs was not always consistent and was not always verified
by a cardiologist. Moreover, the data from carfilzomib trials
carry certain flaws that may inaccurately predict incidence of
CVAEs. For instance, carfilzomib-treated patients were seen
more often which can contribute to ascertainment bias, where-
as post hoc analysis, lack of blinded studies, and studies lack-
ing placebo present additional sources of bias.
Ixazomib (Ninlaro, MLN9708)
Ixazomib, like bortezomib, acts as on a reversible inhibitor on
the β5 (chymotrypsin-like) and β5i subunits of the
immunoproteasome, with additional inhibition of β1 and β2
subunits at higher concentrations [77, 78]. Ixazomib was the
first orally bioavailable drug approved by the FDA in 2015 for
RRMM used in combination with lenalidomide and dexa-
methasone for patients in which 1 or more prior lines of treat-
ment failed. Its approval followed the TOURMALINE-MM1
trial [79•]. This randomized phase III trial compared ixazomib
versus placebo in combination with lenalidomide and dexa-
methasone and found that PFS was significantly longer with
ixazomib with limited toxic effects (nausea and vomiting were
most common). With regard to CVAEs, the trial showed that
HTN, HF, arrhythmia, and MI did not differ significantly be-
tween the two groups. This is possible due to the reversibility
of proteasome inhibition with ixazomib, similar to that with
bortezomib. However, the trial did exclude patients with clin-
ical symptoms of arrhythmia, HTN, HF, unstable angina, or
myocardial infarction within the previous 6 months. Of note,
ixazomib-dexamethasone has been used safely in relapsed or
refractory primary systemic AL amyloidosis where cardiac
involvement is present, although in the trial, the primary end-
point of hematologic response was not met [80].
Other Proteasome Inhibitors
Oprozomib (ONX 0912, PR-047), like carfilzomib, is an
epoxyketone PI that is orally bioavailable. As a structural ho-
molog of carfilzomib, it irreversibly binds to the β5 subunits.
Phase I/II data suggest that oprozomib could have clinical
activity in MM, both in RRMM [81•] and NDMM [82•].
While GI side effects were commonly reported, there is some
evidence for peripheral neuropathy with relatively few cardio-
vascular side effects. Only some recent data has evaluated
ECG data [83], which have not proved to be useful in detect-
ing cardiotoxicity in carfilzomib trials [35••, 84]. It will be
essential to test for CVAE mediated by this drug since its
structure and mechanism are equivalent to that of carfilzomib.
Marizomib (NPI-0052) is a salinosporamide that acts as an
irreversible PI of the β5 and β2 subunits of the proteasome.
The drug has a unique efficacy and safety profile, with little
cross-resistance with other PIs. There are currently several
phase I trials using marizomib that demonstrate promising
activity in RRMM [85, 86], with phase II trials underway.
Little data regarding CVAE from this drug is available.
Curr Oncol Rep           (2020) 22:66 Page 7 of 14    66 
Overall, despite reports of cardiotoxicity from PIs, it is
difficult to establish the extent to which reported cardiopul-
monary events were attributable to patients’ baseline comor-
bidities or toxicity from previous or current treatments.
Studies that factor in detailed accounts of previous cardiovas-
cular history and prior treatment along with concomitant anti-
myeloma agent usage are in need.
Discussion: Diagnosis and Treatment
Despite the lack of clear guidelines on the diagnosis and treat-
ment of proteasome inhibitor-related cardiotoxicity, there are
general recommendations regarding the management of other
associated cardiovascular disorders drawn from real-world
clinical experience (Table 2). Although carfilzomib has been
the predominant drug for which studies have created an ex-
tensive profile for cardiotoxicity, broad guidelines for other
newer PIs may be extrapolated from experience with
carfilzomib.
Early Detection
It is essential that clinicians gather a clear history from patients
so that cardiovascular risk factors are optimized prior to initi-
ation of PIs. Most reports of cardiotoxicity with carfilzomib
reveal clinical events that occur early during treatment, and
less common late events with no clear relationship with cu-
mulative toxicity [70, 87, 88]. This supports early follow-up
with a cardiovascular clinician after PI treatment. As
carfilzomib is associated with heart failure and hypertension,
it is important to optimize medications for patients with these
conditions. A history of atrial fibrillation and flutter or heart
failure was significantly more prevalent in patients who expe-
rienced CVAEs fromPIs [89]. A case series of 12 patients with
CVAEs after carfilzomib-based treatment determined that pa-
tients had a history of the specific CVAE that they exhibited,
with improvement after discontinuation of the therapy [90].
Finally, in a study of 60 patients, baseline cardiovascular dis-
ease was associated with an increased incidence of cardiac
events (23.5% vs 7%) [91].
While the exposure of cardiomyocytes to toxic insults may
result in transient or subclinical impairments in healthy popu-
lations, patients with baseline dysfunction exacerbated from
underlying cardiac disease, prior drug exposure, or even from
genetic cardiomyopathies have increased sensitivity for addi-
tional hits and may exhibit fulminant CVAEs. In the preclin-
ical rat myocyte model, bortezomib and carfilzomib potenti-
ated cardiotoxic effects of doxorubicin [18]. Clinical evidence
suggests that prior radiation to the chest, anthracycline, or
doxorubicin exposure may all be indicators for higher-risk
susceptibility to the CVAEs induced by carfilzomib, making
these cases attributable to a “multiple hit” phenomenon [34,
74, 90, 92, 93]. This highlights the importance of a careful
history of previous heart conditions along with a clear history
of previous treatments in helping clinicians suspect and diag-
nose carfilzomib-induced cardiotoxicity at an earlier time
point. In patients with higher CVAE risk, certain precautions
may be considered, such as early cardiologist referral before
commencement of treatment if cardiac risk factors are identi-
fied, as well as an oncologist consideration for adjustments of
the rate of infusion or initiation of the drug at a lower dose
with gradual up-titration [74, 90, 94, 95]. Newer agents like
ixazomib or oprozomib, on the other hand, bypass this con-
cern for infusion rates and doses while expanding availability
of PI treatment.
Monitoring for Cardiotoxicity During Proteasome
Inhibitor Therapy
During treatment, certain cardiopulmonary processes known
to be associated with PI administration should be watched
closely. Blood pressure elevations should be treated promptly,
and vitals should be obtained at initial visits to have a baseline
for comparison. Typical symptoms and signs of heart failure
and fluid overload should be evaluated by a cardiologist after
ruling out other etiologies (i.e., pulmonary embolus, pneumo-
nia, anemia, anxiety).
In a recent case series of carfilzomib-treated patients,
treatment-emergent dyspnea and left ventricular systolic and/
Table 2 Assessment and management of proteasome inhibitor-
mediated cardiotoxicity
Pre-treatment optimization
Assess baseline cardiovascular risk (clinical, EKG, TTE, +/− stress test)
Identify unique cardiovascular risk factors (i.e., prior stem cell transplant,
prior heavy cytotoxic treatment, prior anthracyclines, concurrent AL
amyloid)
Control pre-existing cardiovascular risk factors
Utilize goal-directed medical therapy for patients with heart failure
(beta-blockers, ACE inhibitors, ARBs, aldosterone antagonists,
diuretics)
Monitoring during treatment
Promptly evaluate any new cardiovascular symptom
Consider reducing IV fluid rates/volumes in patients with risk factors for
volume overload
Consider VTE prophylaxis in high-risk patients
Consider holding treatment with development of cardiotoxicity (i.e.,
clinical HF, ventricular dysfunction) and weighting of risks and
benefits of continuing therapy
Post-treatment assessment
Work up any cardiovascular signs or symptoms emerging after therapy
(first rule out PE, asthma/COPD, respiratory infection)
Continue clinical follow-ups tailored to pre-treatment cardiovascular
disease and on-treatment morbidity
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or diastolic dysfunction were described in 6 patients [92]. The
investigators did not find troponin to be having predictive
capacity [35••]. Following BNP levels is common in other
reports, including a patient on carfilzomib as a phase Ib clin-
ical trial [96], a case series of 12 patients [90], the PROTECT
study [35••], and a retrospective analysis from University of
Arkansas [97], to name a few. However, it is difficult to dis-
cern whether or not elevations in BNP levels correlate with
increased clinical symptoms or hospitalizations [34, 74], and
RCTs will be needed to answer this question definitively. It
may be helpful to obtain baseline BNP levels prior to initiating
a PI and trend BNP at the discretion of the provider, especially
during the mid-first cycle of therapy for carfilzomib and for
the first 3 months of therapy [35••]. However, changes to
chemotherapy should not be based solely on BNP levels, as
patients would often have BNP elevation without associated
symptoms or hospitalizations. New BNP elevations may war-
rant closer monitoring for changes in body weights and regu-
lar assessment for fluid overload. As previously mentioned,
electrocardiographic LVH has little utility in screening for
cardiotoxicity. Similarly, TTE has limited value for predicting
or demonstration CVAEs, with variable findings of associated
normal systolic and diastolic function as well as abnormal LV
longitudinal strain [34, 74, 90, 92]. However, even though
large trials like ENDEAVOR suggest that there is limited util-
ity of serial echocardiography as a risk mitigation tool for
patients receiving carfilzomib, this is difficult to extrapolate
to patients with more baseline cardiac comorbidities since
ENDEAVOR excluded such patients. Monitoring with echo-
cardiography may help detect subclinical or impending pul-
monary hypertension and heart failure in patients prior to ther-
apy, and should still be standard of care, especially in the case
in patients of advanced age, with prior risk factors
(anthracyclines, doxorubicin, radiation therapy), risks for am-
yloidosis, or other cardiovascular risk factors. In the future,
further assessment on LV longitudinal strain or other imaging
strategies may provide more sensitive, non-invasive detection
of cardiotoxicities and prove useful in ruling out alternative
causes.
Management of Cardiotoxicity
In patients scheduled for carfilzomib therapy who have risk
factors for cardiotoxicity, practitioners may consider prophy-
lactic measures, as well as typical methods to manage heart
failure should it arise. Prophylactically, reduction in intrave-
nous fluid volume to be administered with PI infusions, along
with prolongation of infusion time of carfilzomib may lead to
better tolerability for the therapy. Typically, patients receive
1.5 to 6 l of fluids in cycle 1 of therapy, and about 250–
500 mL prior to each treatment over 6 treatments, with addi-
tional 250–500 mL if needed following administration of
carfilzomib [98]. Since this fluid is mainly to reduce tumor
lysis syndrome, in the setting of chronic renal failure, or to
prevent and reduce fatigue, the amount of fluid may be adjust-
ed on an individual patient basis. This is especially true in
cases of chronic heart failure, stable renal function, elderly
patients over age 75, and cardiac risk factors. Since patients
receiving PI infusions with corticosteroid are also vulnerable
to fluid overload from the fluid-retaining properties of the
steroids, reduction of fluids with each cycle may be appropri-
ate. For patients with a history of chronic heart failure, man-
agement of heart failure by a cardiologist with goal-directed
medical therapy is ideal, including beta-blockers and diuretics.
Addition of cardiovascular medications, particularly anti-hy-
pertensives, may also be appropriate given the effect
carfilzomib plays on the endothelium which leads to common
side effects of hypertension. In patients with stable renal func-
tion, ACE inhibitors or ARBs may serve the dual purpose as
heart failure medication for beneficial ventricular remodeling
and anti-hypertensive.
In patients who present with overt signs of cardiotoxicity,
clinicians should first rule out alternative etiologies for dys-
pnea, hypertension, chest pain, and heart failure.
Manufacturer-based guidelines for the management of non-
hematologic toxicities for patients on lenalidomide and
carfilzomib endorse resuming full dose of lenalidomide with
modifications on dosing of carfilzomib. These three
carfilzomib modifications are listed as follows: (1) for CHF,
hold dose until resolution or return to baseline, after which
may result at a reduced dose or permanently discontinue. If
no resolution after 4 weeks, subject to be withdrawn from all
study treatment, (2) for HTN crisis (SBP sustained > 180 or
DBP > 110), hold carfilzomib until resolution to baseline, then
resume at 1 dose decrement; (3) LVEF reduction < 40% or <
55% if drop is greater than 20% from baseline, hold
carfilzomib until LVEF returns to ≥ 40. Resume at 1 dose
decrement; and (4) if held due to LVEF drop < 55%, hold
carfilzomib until LVEF returns to within 15% of baseline.
Resume at 1 dose decrement. [98].Mount Sinai lists a succinct
institutional guideline which recommends holding
carfilzomib until toxicity resolves to grade < 2, and if decision
is made to re-challenge the patients, a dose reduction may be
considered [90].
Modification of dosing for carfilzomib may be useful even
with the irreversibility of the drug as cases show that with-
drawal or dose reduction with initiation of heart failure med-
ications may potentially reverse cardiomyopathy, while others
show resolved cardiac dysfunction while resuming these med-
ications [90, 91, 99]. Hemodialysis has not been found to be
helpful to enhance elimination since there is 97% plasma pro-
tein binding of carfilzomib [98]. Further understanding of the
potential mechanisms that lead to carfilzomib-induced
cardiotoxicity through pre-clinical data is useful in under-
standing alternative methods for preventing and treating these
adverse events.
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Future Directions
Based on proposed mechanisms for cardiotoxicity, various
new agents have been presented to counteract PI-related
cardiotoxicity. Animal model studies have noted that three
compounds named rutin, dexrazoxane, and apremilast have
been shown to reverse carfilzomib-induced cardiotoxicity in
rat models. Rutin, or vitamin P, is a bioflavonoid that was
found in rat hearts to inhibit NF-κB, directly reducing patho-
logic hypertrophic remodeling and oxidative stress [100•]. In
this study, rutin was able to decrease cardiac enzyme release
and cause upregulation of α-MHC mRNA expression with
downregulation of β-MHC and BNP mRNA expression.
Overall, the vitamin was able to reverse histopathological
changes in the heart induced by carfilzomib. The exact mech-
anisms through which rutin was able to achieve this endpoint
is still unclear. Interestingly, dexrazoxane, an inhibitor of
topoisomerase IIB and free radical scavenger that had previ-
ously been found to be cardioprotective in doxorubicin-
induced cardiotoxicity [101], was found to perform similarly
to rutin in rat cardiomyocytes [102•]. Finally, a PDE4 inhibitor
called apremilast that is used in psoriasis for its anti-
inflammatory effect was also found in rat models to have
similar ability to reverse carfilzomib-induced cardiotoxicity
[103•]. The drug additionally demonstrated reversal of the
increased NF-κB, ERK, and JNK mRNA expression along
with reversal of increased inflammatory markers such as
TNF-α that was seen with carfilzomib treatment. Provided
that this evidence is weak for cardioprotective effect of rutin,
dexrazoxane, and apremilast against carfilzomib as they have
only been demonstrated in rat models at one institution, these
are still far from being applicable in the clinical setting.
An alternative approach to reduce cardiotoxicity involves
adapting current PIs to curtail their off-target effects on the
heart. For example, the findings of carfilzomib-related inacti-
vation of autophagy proteins in mice indicate a prophylactic
role for metformin for its known effects of AMPKα activa-
tion, autophagy regulation, and apoptosis inhibition [33••]. In
this study, metformin treatment was able to protect mice from
cardiotoxicity without interfering with proteasome inhibition.
Of note, bortezomib administration did not result in similar
findings when compared with carfilzomib, suggesting a
unique mechanism for carfilzomib toxicity. Another method
that works further upstream involves the modification of drugs
for proteasome inhibition to selectively target the
immunoproteasome with minimal inhibition of the constitu-
tive proteasome. Some of the currently available
immunoproteasomes include UK-101 and IPSI-001 which
are specific to the β1i subunit. Of note, IPSI-001 has demon-
strated effectiveness in MM cell line models and in patient
samples with hematological malignancies, even in setting of
bortezomib resistance with fewer toxicities towards nonma-
lignant cells [104]. PR-924 has similar findings, with
additional findings in mouse xenograft models of MM
[105]. Development of more clinically applicable selective
immunoproteasome inhibitors will be possible with increased
understanding of the structural differences between the con-
stitutive and the inducible proteasomes. For example, the find-
ing of the crystal structure of murine immunoproteasome has
revealed key structural differences between the β5 and β5i
catalytic subunits that explain the observed selectively of ON
0914 for the immunoproteasome [106].
Finally, the administration of current PIs may be modified
with regard to route of delivery, dosing, and infusion times.
For example, a phase III trial conducted by the Intergroupe
Francophone duMyelome (IFM) demonstrated that neurotox-
icity risk could also be reduced by subcutaneous administra-
tion [107], leading to its approval by the FDA in 2012 for
subcutaneous administration. In fact, a meta-analysis for sub-
cutaneous versus intravenous bortezomib suggested that sub-
cutaneous route might also reduce incidence of thrombocyto-
penia, renal, and urinary disorders [108•]. Examples of de-
creasing neurotoxicity without losing efficacy have also been
seen with bortezomib by using a reduced-intensity regimen
and extending infusion time to a weekly schedule [107,
109–111]. Similar changes to carfilzomib may be able to re-
duce some of its cardiotoxic side effects, but it remains to be
seen whether or not changing carfilzomib’s route of adminis-
tration, dosing, or interval would impact its effectiveness.
Along this vein, oprozomib is an extremely appealing alterna-
tive, as it is an oral homolog of carfilzomib and thus far has not
been found to have associated cardiotoxicity.
Conclusion
The development of highly efficacious and targeted anti-
myeloma therapies has led to advancements in treatment regi-
mens with significantly improved response and survival out-
comes. This quickly expanding armamentarium of potent thera-
pies necessitates careful pre-clinical and clinical experimental
design to accurately identify emerging treatment-related adverse
events. Since previous studies involving PIswere not designed to
specifically detect cardiotoxicity, the precise incidence of CVAEs
that can be directly attributed to the drug is difficult to discern. In
particular, carfilzomib, which has demonstrated the most clini-
cally significant CVAEs, and newer agents such as ixazomib,
oprozomib, and marizomib warrant increased cardiovascular
scrutiny in order to determine whether these toxicities are attrib-
utable to the drug class as a whole.
Ideally, concomitant prospective tracking of CVAEs in clini-
cal trials using PIs would be ideal, with consistent protocols of
using biomarkers and cardiovascular imaging in order to identify
individuals at risk for developing cardiotoxicity. Uniform cardio-
vascular evaluation protocols to establish patients’ baseline char-
acteristics, biochemical and immunological profile throughout
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the study, and post-trial surveillance are needed to better under-
stand the true incidence of cardiotoxicity, its risk factors, natural
history, and most effective management strategies. In addition,
national/international registries should be assembled to track the
“real-world” and long-term effects of these agents used in the
general population in order to effectively devise cardioprotective
and surveillance strategies for cardiotoxicity. Such collaborations
between cardiology and hematology could potentially allow for
present and future cancer treatments of MM to proceed with
attenuated cardiotoxicity risk with cardioprotective and imaging
strategies and provide mechanistic insight into the development
of heart failure that may benefit the general population as a
whole.
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